{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,21]],"date-time":"2026-05-21T00:06:05Z","timestamp":1779321965506,"version":"3.51.4"},"reference-count":50,"publisher":"Oxford University Press (OUP)","issue":"5","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,5,20]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) lineage-specific coronavirus disease 2019 (COVID-19) vaccine effectiveness (VE) studies can inform decision-making on whether vaccine composition updates are needed to maintain effectiveness against severe disease as SARS-CoV-2 continues to evolve. Lineage assignment methods in VE test-negative design (TND) studies include sequence-based (whole-genome sequencing), proxy-based (eg, S-gene target failure during polymerase chain reaction), and time period-based (using variant predominance thresholds) approaches.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We first summarize benefits, challenges (including cost and timeliness), and methodologic considerations for estimating lineage-specific COVID-19 VE using these different assignment approaches. We then use a deterministic model to illustrate the potential impact of lineage misclassification error on VE estimates in a TND using period-based versus sequence-based lineage assignment across different variant emergence scenarios.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Our model suggests period-based analyses may sometimes underestimate differences in VE between 2 lineages due to lineage misclassification error. This effect is most evident during prolonged variant cocirculation or in early time periods following new variant takeover. Using higher predominance thresholds can reduce VE estimate bias in period-based analyses but at the expense of sample size, reducing precision or outright precluding estimation under some scenarios. Period-based VE analyses should therefore consider including sensitivity analyses to characterize robustness of VE estimates to different predominance thresholds.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>TND studies using sequence-, proxy-, and period-based lineage assignment have contributed substantially toward understanding SARS-CoV-2 variant-mediated vaccine escape, but biases that can affect each study design vary. Our results identify analytic considerations for robust estimation and suggest principles that may translate to other pathogens that undergo continuous antigenic drift.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/cid\/ciag059","type":"journal-article","created":{"date-parts":[[2026,1,30]],"date-time":"2026-01-30T12:47:15Z","timestamp":1769777235000},"page":"e932-e941","source":"Crossref","is-referenced-by-count":0,"title":["Integrating Genomic Data into Test-negative Designs for Estimating Lineage-specific COVID-19 Vaccine Effectiveness"],"prefix":"10.1093","volume":"82","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4326-2911","authenticated-orcid":false,"given":"Kevin C","family":"Ma","sequence":"first","affiliation":[{"name":"National Center for Immunization and Respiratory Diseases, Centers for Disease Control and Prevention (CDC) , Atlanta, Georgia ,","place":["USA"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3931-1423","authenticated-orcid":false,"given":"Diya","family":"Surie","sequence":"additional","affiliation":[{"name":"National Center for Immunization and Respiratory Diseases, Centers for Disease Control and Prevention (CDC) , Atlanta, Georgia ,","place":["USA"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3884-0921","authenticated-orcid":false,"given":"Natalie E","family":"Dean","sequence":"additional","affiliation":[{"name":"Rollins School of Public Health, Emory University , Atlanta, Georgia ,","place":["USA"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Clinton R","family":"Paden","sequence":"additional","affiliation":[{"name":"National Center for Immunization and Respiratory Diseases, Centers for Disease Control and Prevention (CDC) , Atlanta, Georgia ,","place":["USA"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3523-3616","authenticated-orcid":false,"given":"Natalie J","family":"Thornburg","sequence":"additional","affiliation":[{"name":"National Center for Immunization and Respiratory Diseases, Centers for Disease Control and Prevention (CDC) , Atlanta, Georgia ,","place":["USA"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fatimah S","family":"Dawood","sequence":"additional","affiliation":[{"name":"National Center for Immunization and Respiratory Diseases, Centers for Disease Control and Prevention (CDC) , Atlanta, Georgia ,","place":["USA"]}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2026,2,2]]},"reference":[{"key":"2026052019240438200_ciag059-B1","doi-asserted-by":"crossref","first-page":"1205","DOI":"10.1038\/s41591-021-01377-8","article-title":"Neutralizing antibody levels are highly predictive of immune protection from symptomatic SARS-CoV-2 infection","volume":"27","author":"Khoury","year":"2021","journal-title":"Nat Med"},{"key":"2026052019240438200_ciag059-B2","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41467-024-52194-9","article-title":"Predicting COVID-19 booster immunogenicity against future SARS-CoV-2 variants and the benefits of vaccine updates","volume":"15","author":"Cromer","year":"2024","journal-title":"Nat Commun"},{"key":"2026052019240438200_ciag059-B3","doi-asserted-by":"crossref","first-page":"776","DOI":"10.1038\/s41591-023-02220-y","article-title":"When to update COVID-19 vaccine composition","volume":"29","author":"Grant","year":"2023","journal-title":"Nat Med"},{"key":"2026052019240438200_ciag059-B4","doi-asserted-by":"crossref","first-page":"eadj3747","DOI":"10.1126\/sciadv.adj3747","article-title":"Design and analysis heterogeneity in observational studies of COVID-19 booster effectiveness: a review and case study","volume":"9","author":"Meah","year":"2023","journal-title":"Sci Adv"},{"key":"2026052019240438200_ciag059-B5","doi-asserted-by":"crossref","first-page":"995","DOI":"10.1016\/j.vaccine.2023.12.013","article-title":"Test negative design for vaccine effectiveness estimation in the context of the COVID-19 pandemic: a systematic methodology review","volume":"42","author":"M\u00e9sidor","year":"2024","journal-title":"Vaccine"},{"key":"2026052019240438200_ciag059-B6","doi-asserted-by":"crossref","first-page":"127567","DOI":"10.1016\/j.vaccine.2025.127567","article-title":"Analytical approaches and examples of addressing time-varying factors in COVID-19 vaccine effectiveness studies: report from a meeting of the World Health Organization","volume":"62","author":"Varma","year":"2025","journal-title":"Vaccine"},{"key":"2026052019240438200_ciag059-B7","doi-asserted-by":"crossref","first-page":"2329","DOI":"10.1016\/j.vaccine.2023.02.020","article-title":"Assessing COVID-19 vaccine effectiveness against Omicron subvariants: report from a meeting of the World Health Organization","volume":"41","author":"Feikin","year":"2023","journal-title":"Vaccine"},{"key":"2026052019240438200_ciag059-B8","doi-asserted-by":"crossref","first-page":"18968","DOI":"10.1038\/s41598-022-21564-y","article-title":"The spike gene target failure (SGTF) genomic signature is highly accurate for the identification of Alpha and Omicron SARS-CoV-2 variants","volume":"12","author":"McMillen","year":"2022","journal-title":"Sci Rep"},{"key":"2026052019240438200_ciag059-B9","doi-asserted-by":"crossref","first-page":"125","DOI":"10.15585\/mmwr.mm7205e2","article-title":"Spike gene target amplification in a diagnostic assay as a marker for public health monitoring of emerging SARS-CoV-2 variants\u2014United States, November 2021\u2013January 2023","volume":"72","author":"Scobie","year":"2023","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"2026052019240438200_ciag059-B10","author":"World Health Organization"},{"key":"2026052019240438200_ciag059-B11","doi-asserted-by":"crossref","first-page":"1715","DOI":"10.1038\/s41591-022-01877-1","article-title":"Rapid evaluation of COVID-19 vaccine effectiveness against symptomatic infection with SARS-CoV-2 variants by analysis of genetic distance","volume":"28","author":"Cao","year":"2022","journal-title":"Nat Med"},{"key":"2026052019240438200_ciag059-B12","author":"Kwon"},{"key":"2026052019240438200_ciag059-B13","doi-asserted-by":"publisher","author":"Antunes","DOI":"10.1101\/2025.06.24.25330183"},{"key":"2026052019240438200_ciag059-B14","doi-asserted-by":"crossref","first-page":"106177","DOI":"10.1016\/j.jinf.2024.106177","article-title":"Effectiveness of autumn 2023 COVID-19 vaccination and residual protection of prior doses against hospitalisation in England, estimated using a test-negative case-control study","volume":"89","author":"Kirsebom","year":"2024","journal-title":"J Infect"},{"key":"2026052019240438200_ciag059-B15","doi-asserted-by":"crossref","first-page":"e595","DOI":"10.1093\/cid\/ciae405","article-title":"Effectiveness of updated 2023\u20132024 (monovalent XBB.1.5) COVID-19 vaccination against SARS-CoV-2 Omicron XBB and BA.2.86\/JN.1 lineage hospitalization and a comparison of clinical severity-IVY network, 26 hospitals, 18 October 2023\u20139 March 2024","volume":"82","author":"Ma","year":"2026","journal-title":"Clin Infect Dis"},{"key":"2026052019240438200_ciag059-B16","doi-asserted-by":"publisher","author":"Ma","DOI":"10.1001\/jamanetworkopen.2025.57415"},{"key":"2026052019240438200_ciag059-B17","doi-asserted-by":"crossref","first-page":"2053","DOI":"10.1093\/cid\/ciab762","article-title":"Association of E484K spike protein mutation with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection in vaccinated persons: Maryland, January\u2013May 2021","volume":"74","author":"Feder","year":"2022","journal-title":"Clin Infect Dis"},{"key":"2026052019240438200_ciag059-B18","doi-asserted-by":"crossref","first-page":"e1009406","DOI":"10.1371\/journal.ppat.1009406","article-title":"Sieve analysis to understand how SARS-CoV-2 diversity can impact vaccine protection","volume":"17","author":"Rolland","year":"2021","journal-title":"PLoS Pathog"},{"key":"2026052019240438200_ciag059-B19","doi-asserted-by":"crossref","first-page":"1417","DOI":"10.1016\/S1473-3099(22)00512-6","article-title":"Maintaining genomic surveillance using whole-genome sequencing of SARS-CoV-2 from rapid antigen test devices","volume":"22","author":"Martin","year":"2022","journal-title":"Lancet Infect Dis"},{"key":"2026052019240438200_ciag059-B20","doi-asserted-by":"crossref","first-page":"1384","DOI":"10.1093\/infdis\/jiae400","article-title":"Association between SARS-CoV-2 viral load and COVID-19 vaccination in 4 phase 3 trials","volume":"230","author":"Janes","year":"2024","journal-title":"J Infect Dis"},{"key":"2026052019240438200_ciag059-B21","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1186\/s13690-021-00709-x","article-title":"Conceptual causal framework to assess the effect of SARS-CoV-2 variants on COVID-19 disease severity among hospitalized patients","volume":"79","author":"Van Goethem","year":"2021","journal-title":"Arch Public Health"},{"key":"2026052019240438200_ciag059-B22","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41467-023-43391-z","article-title":"Systematic detection of co-infection and intra-host recombination in more than 2 million global SARS-CoV-2 samples","volume":"15","author":"Pipek","year":"2024","journal-title":"Nat Commun"},{"key":"2026052019240438200_ciag059-B23","doi-asserted-by":"crossref","first-page":"2582","DOI":"10.1056\/NEJMc2103227","article-title":"Tracking the emergence of SARS-CoV-2 alpha variant in the United Kingdom","volume":"385","author":"Walker","year":"2021","journal-title":"N Engl J Med"},{"key":"2026052019240438200_ciag059-B24","doi-asserted-by":"crossref","first-page":"e0275150","DOI":"10.1371\/journal.pone.0275150","article-title":"Validation of reduced S-gene target performance and failure for rapid surveillance of SARS-CoV-2 variants","volume":"17","author":"Clark","year":"2022","journal-title":"PLoS One"},{"key":"2026052019240438200_ciag059-B25","doi-asserted-by":"crossref","first-page":"e0251321","DOI":"10.1128\/spectrum.02513-21","article-title":"Emergency SARS-CoV-2 variants of concern: novel multiplex real-time RT-PCR assay for rapid detection and surveillance","volume":"10","author":"Chung","year":"2022","journal-title":"Microbiol Spectr"},{"key":"2026052019240438200_ciag059-B26","doi-asserted-by":"crossref","first-page":"1042","DOI":"10.1093\/clinchem\/hvac081","article-title":"Multiplex fragment analysis for flexible detection of all SARS-CoV-2 variants of concern","volume":"68","author":"Clark","year":"2022","journal-title":"Clin Chem"},{"key":"2026052019240438200_ciag059-B27","doi-asserted-by":"crossref","first-page":"1063","DOI":"10.1038\/s41591-022-01753-y","article-title":"Effectiveness of mRNA-1273 against SARS-CoV-2 Omicron and Delta variants","volume":"28","author":"Tseng","year":"2022","journal-title":"Nat Med"},{"key":"2026052019240438200_ciag059-B28","doi-asserted-by":"crossref","first-page":"119","DOI":"10.15585\/mmwr.mm7205e1","article-title":"Early estimates of bivalent mRNA booster dose vaccine effectiveness in preventing symptomatic SARS-CoV-2 infection attributable to omicron BA.5\u2013 and XBB\/XBB.1.5\u2013related sublineages among immunocompetent adults\u2014increasing community access to testing program, United States, December 2022\u2013January 2023","volume":"72","author":"Link-Gelles","year":"2023","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"2026052019240438200_ciag059-B29","doi-asserted-by":"crossref","first-page":"77","DOI":"10.15585\/mmwr.mm7304a2","article-title":"Early estimates of updated 2023\u20132024 (monovalent XBB.1.5) COVID-19 vaccine effectiveness against symptomatic SARS-CoV-2 infection attributable to co-circulating omicron variants among immunocompetent adults\u2014increasing community access to testing program, United States, September 2023\u2013January 2024","volume":"73","author":"Link-Gelles","year":"2024","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"2026052019240438200_ciag059-B30","doi-asserted-by":"crossref","first-page":"321","DOI":"10.3390\/microorganisms12020321","article-title":"S-gene target failure as an effective tool for tracking the emergence of dominant SARS-CoV-2 variants in Switzerland and Liechtenstein, including Alpha, Delta, and Omicron BA.1, BA.2, and BA.4\/BA.5","volume":"12","author":"Hilti","year":"2024","journal-title":"Microorganisms"},{"key":"2026052019240438200_ciag059-B31","doi-asserted-by":"crossref","first-page":"4738","DOI":"10.1038\/s41467-022-31838-8","article-title":"Protection of COVID-19 vaccination and previous infection against Omicron BA.1, BA.2 and Delta SARS-CoV-2 infections","volume":"13","author":"Andeweg","year":"2022","journal-title":"Nat Commun"},{"key":"2026052019240438200_ciag059-B32","doi-asserted-by":"crossref","first-page":"e2233273","DOI":"10.1001\/jamanetworkopen.2022.33273","article-title":"Estimation of COVID-19 mRNA vaccine effectiveness against medically attended COVID-19 in pregnancy during periods of Delta and Omicron variant predominance in the United States","volume":"5","author":"Schrag","year":"2022","journal-title":"JAMA Netw Open"},{"key":"2026052019240438200_ciag059-B33","doi-asserted-by":"crossref","first-page":"938","DOI":"10.15585\/mmwr.mm7342a1","article-title":"Genomic surveillance for SARS-CoV-2 variants: circulation of Omicron XBB and JN.1 lineages \u2014United States, May 2023\u2013September 2024","volume":"73","author":"Ma","year":"2024","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"2026052019240438200_ciag059-B34","doi-asserted-by":"crossref","first-page":"7003","DOI":"10.1038\/s41467-022-33713-y","article-title":"Global disparities in SARS-CoV-2 genomic surveillance","volume":"13","author":"Brito","year":"2022","journal-title":"Nat Commun"},{"key":"2026052019240438200_ciag059-B35","doi-asserted-by":"crossref","first-page":"651","DOI":"10.15585\/mmwr.mm7224a2","article-title":"Genomic surveillance for SARS-CoV-2 variants: circulation of Omicron lineages\u2014United States, January 2022\u2013May 2023","volume":"72","author":"Ma","year":"2023","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"2026052019240438200_ciag059-B36","doi-asserted-by":"crossref","first-page":"1980","DOI":"10.1093\/cid\/ciac290","article-title":"Two-dose severe acute respiratory syndrome coronavirus 2 vaccine effectiveness with mixed schedules and extended dosing intervals: test-negative design studies from British Columbia and Quebec, Canada","volume":"75","author":"Skowronski","year":"2022","journal-title":"Clin Infect Dis"},{"key":"2026052019240438200_ciag059-B37","doi-asserted-by":"crossref","first-page":"e069761","DOI":"10.1136\/bmj-2021-069761","article-title":"Clinical severity of, and effectiveness of mRNA vaccines against, COVID-19 from omicron, delta, and alpha SARS-CoV-2 variants in the United States: prospective observational study","volume":"376","author":"Lauring","year":"2022","journal-title":"BMJ"},{"key":"2026052019240438200_ciag059-B38","doi-asserted-by":"crossref","first-page":"e072065","DOI":"10.1136\/bmj-2022-072065","article-title":"Vaccine effectiveness of primary series and booster doses against COVID-19 associated hospital admissions in the United States: living test negative design study","volume":"379","author":"Adams","year":"2022","journal-title":"BMJ"},{"key":"2026052019240438200_ciag059-B39","doi-asserted-by":"crossref","first-page":"1663","DOI":"10.1016\/S1473-3099(22)00692-2","article-title":"BNT162b2 vaccine effectiveness against SARS-CoV-2 omicron BA.4 and BA.5","volume":"22","author":"Tartof","year":"2022","journal-title":"Lancet Infect Dis"},{"key":"2026052019240438200_ciag059-B40","doi-asserted-by":"crossref","first-page":"964","DOI":"10.1016\/S1473-3099(24)00220-2","article-title":"Relative vaccine protection, disease severity, and symptoms associated with the SARS-CoV-2 omicron subvariant BA.2.86 and descendant JN.1 in Denmark: a nationwide observational study","volume":"24","author":"Moustsen-Helms","year":"2024","journal-title":"Lancet Infect Dis"},{"key":"2026052019240438200_ciag059-B41","doi-asserted-by":"crossref","first-page":"100755","DOI":"10.1016\/j.lanepe.2023.100755","article-title":"Vaccine effectiveness against hospitalisation estimated using a test-negative case-control study design, and comparative odds of hospital admission and severe outcomes with COVID-19 sub-lineages BQ.1, CH.1.1. and XBB.1.5 in England","volume":"35","author":"Kirsebom","year":"2023","journal-title":"Lancet Reg Health Eur"},{"key":"2026052019240438200_ciag059-B42"},{"key":"2026052019240438200_ciag059-B43","doi-asserted-by":"publisher","author":"Carazo","DOI":"10.1371\/journal.pone.0325269"},{"key":"2026052019240438200_ciag059-B44","doi-asserted-by":"crossref","first-page":"1601","DOI":"10.1017\/S095026881500309X","article-title":"Regression approaches in the test-negative study design for assessment of influenza vaccine effectiveness","volume":"144","author":"Bond","year":"2016","journal-title":"Epidemiol Infect"},{"key":"2026052019240438200_ciag059-B45","doi-asserted-by":"crossref","first-page":"e2517402-e2517402","DOI":"10.1001\/jamanetworkopen.2025.17402","article-title":"Estimated 2023\u20132024 COVID-19 vaccine effectiveness in adults","volume":"8","author":"Link-Gelles","year":"2025","journal-title":"JAMA Netw Open"},{"key":"2026052019240438200_ciag059-B46","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1093\/aje\/kwad191","article-title":"Examining bias from differential depletion of susceptibles in vaccine effectiveness estimates in settings of waning","volume":"193","author":"Kahn","year":"2024","journal-title":"Am J Epidemiol"},{"key":"2026052019240438200_ciag059-B47","doi-asserted-by":"crossref","first-page":"10062","DOI":"10.1038\/s41467-024-54404-w","article-title":"Bias and negative values of COVID-19 vaccine effectiveness estimates from a test-negative design without controlling for prior SARS-CoV-2 infection","volume":"15","author":"Wiegand","year":"2024","journal-title":"Nat Commun"},{"key":"2026052019240438200_ciag059-B48","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1093\/infdis\/jiac453","article-title":"Use of whole-genome sequencing to estimate the contribution of immune evasion and waning immunity on decreasing COVID-19 vaccine effectiveness","volume":"227","author":"Lind","year":"2023","journal-title":"J Infect Dis"},{"key":"2026052019240438200_ciag059-B49","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1093\/aje\/kwac203","article-title":"Current challenges with the use of test-negative designs for modeling COVID-19 vaccination and outcomes","volume":"192","author":"Shi","year":"2023","journal-title":"Am J Epidemiol"},{"key":"2026052019240438200_ciag059-B50","doi-asserted-by":"crossref","first-page":"e2512763","DOI":"10.1001\/jamanetworkopen.2025.12763","article-title":"Evaluating the test-negative design for COVID-19 vaccine effectiveness using randomized trial data: a secondary cross-protocol analysis of 5 randomized clinical trials","volume":"8","author":"Andrews","year":"2025","journal-title":"JAMA Netw Open"}],"container-title":["Clinical Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/cid\/advance-article-pdf\/doi\/10.1093\/cid\/ciag059\/66725390\/ciag059.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/cid\/article-pdf\/82\/5\/e932\/66725390\/ciag059.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/cid\/article-pdf\/82\/5\/e932\/66725390\/ciag059.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,20]],"date-time":"2026-05-20T23:24:10Z","timestamp":1779319450000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/cid\/article\/82\/5\/e932\/8456270"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,2]]},"references-count":50,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2026,2,2]]},"published-print":{"date-parts":[[2026,5,20]]}},"URL":"https:\/\/doi.org\/10.1093\/cid\/ciag059","relation":{},"ISSN":["1058-4838","1537-6591"],"issn-type":[{"value":"1058-4838","type":"print"},{"value":"1537-6591","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,5,15]]},"published":{"date-parts":[[2026,2,2]]}}}